Fig. 5
Effect of revefenacin on daily peak expiratory flow rate. a morning PEF (representative of the trough PEF of the prior day’s dosing). b evening PEF, assessed ≈12 h after daily study medication dosing. Data presented as placebo-adjusted LS mean; dotted line (·········) = zero L/min; dashed line (−····) represents LS mean placebo–adjusted increases in AM and PM PEF for revefenacin doses ≥88 μg, which were similar across the treatment period and centered at approximately 27 L/min and 29 L/min, respectively. Abbreviations: LS: least squares; PEFR: peak expiratory flow rate